Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 09:01:51 05/07/2024 pm IST			5-day change	1st Jan Change
243.3 ^CHF	-0.04%		-2.48%	-0.49%

05/07	Global markets live: Apple, Samsung, Shell, Tesla, KKR...
05/07	Trending : Roche to Halt Lung-Cancer Trials After Treatment Misses Goals	DJ

ROCHE HOLDINGS AG : Buy rating from Credit Suisse

January 06, 2023 at 07:55 pm IST

Credit Suisse analyst Dominic Lunn maintains his Buy rating on the stock. The target price has been modified and is now set at CHF 380 compared to CHF 375.

Latest news about Roche Holding AG

Global markets live: Apple, Samsung, Shell, Tesla, KKR...	05/07
Trending : Roche to Halt Lung-Cancer Trials After Treatment Misses Goals	05/07	DJ
ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating	05/07	ZD
Roche: new approval for Vabysmo in the United States	05/07	CF
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating	05/07	ZD
Roche's Prefilled Syringe for Eye Drug Vabysmo Secures US FDA Nod	05/07	MT
Swiss Equities Close Higher as Inflation Eases; Roche Slumps	04/07	MT
Market Update-Europe closes higher on optimism about US rates	04/07	RE
ROCHE HOLDINGS AG : Gets a Sell rating from Goldman Sachs	04/07	ZD
Market Update-European stock markets rise in absence of Wall Street	04/07	RE
ROCHE HOLDINGS AG : UBS sticks Neutral	04/07	ZD
Dax starts trading firmer - US interest rate policy in focus	04/07	RE
ROCHE HOLDINGS AG : Sell rating from JP Morgan	04/07	ZD
European shares advance on rate optimism; UK elections in focus	04/07	RE
Roche: study in lung cancer fails and is discontinued	04/07	CF
Roche to halt trial in latest setback for new cancer drug	04/07	RE
Roche to Halt Lung Cancer Trial After Results Miss Goals	04/07	DJ
Roche to Halt Trial of Combination Formulation for Non-small Cell Lung Cancer Treatment	04/07	MT
Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer	04/07	CI
ROCHE HOLDINGS AG : Berenberg sticks Neutral	03/07	ZD
Goldman Sachs Lowers Price Target on Roche, Maintains Sell Recommendation	02/07	MT
ROCHE HOLDINGS AG : Jefferies reiterates its Neutral rating	02/07	ZD
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating	02/07	ZD
'HB': Sanofi plans to invest billions in Frankfurt	01/07	DP
ROCHE HOLDINGS AG : Deutsche Bank remains Neutral	01/07	ZD

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

23/07/2024 - American Society of Retina Specialists Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 09:20 pm IST

Obesity: Roche joins the battle

December 04, 2023 at 09:18 pm IST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

243.3 CHF

Average target price

276.6 CHF

Spread / Average Target

+13.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-0.49%	22TCr
ELI LILLY AND COMPANY	+56.89%	82TCr
NOVO NORDISK A/S	+39.52%	63TCr
JOHNSON & JOHNSON	-6.55%	35TCr
MERCK & CO., INC.	+15.99%	32TCr
ABBVIE INC.	+7.92%	30TCr
ASTRAZENECA PLC	+13.74%	24TCr
NOVARTIS AG	+13.83%	22TCr
AMGEN INC.	+7.94%	17TCr
PFIZER, INC.	-2.57%	16TCr

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Buy rating from Credit Suisse

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals